Losses narrow at MediGene but still no deal for EndoTAG-1
This article was originally published in Scrip
MediGene reported a reduced net loss for 2009, from around €31 million to €22 million, on unchanged revenues of about $40 million. The German biotech company is still waiting to sign a much-needed partnership for its lead development candidate EndoTAG-1 but it hopes to increase revenue for 2010 through product sales alone.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.